Pre-exposure prophylaxis in the EU/EEA. PrEP service delivery and monitoring: minimum standards and key principles
In a two-day meeting organised by ECDC and UNAIDS, representatives of 22 European countries discussed how to improve the delivery of HIV pre-exposure prophylaxis (PrEP) across Europe. The meeting brought together country delegates, PrEP users and community HIV advocates to seek ways to strengthen the provision and monitoring of PrEP.
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA
The scope of this project was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings.
Call for scientific collaboration to support genomic-based surveillance of Neisseria gonorrhoeae-antimicrobial resistance at EU-level
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.
Surveillance systems overview for 2017
This spreadsheet contains all surveillance system overview tables from ECDC's annual epidemiological report for 2017.
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- hantavirus infection
- healthcare-associated infections
- hepatitis A
- hepatitis B
- hepatitis C
- HIV infection
- invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- meningococcal disease
- pneumococcal disease
- Q fever
- Rift Valley fever
- severe acute respiratory syndrome
- surgical site infections
- verotoxigenic Escherichia coli infection
- West Nile fever
- yellow fever
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Infographic: HIV and AIDS in Europe 2017
Europe experiences a persistent HIV epidemic, with only little changes in notifications during the last decade in the EU/EEA. One reason for this: an estimated 120 000 Europeans are living with undiagnosed HIV in the EU/EEA, which means that about 1 in 5 (15 %) of those living with HIV are not aware of their status. And it takes around three years from HIV infection to diagnosis.
Infographic: HIV late Diagnosis - 2017 data
In the EU/EEA, almost every second HIV diagnosis happened at a late stage in 2017. This means diagnosis several years after infection.
In 2007, 49 % of those with a CD4 cell count reported at HIV diagnosis were diagnosed late (several years after infection).
Ending the HIV epidemic: where does Europe stand?
From diagnosis of HIV to successful viral suppression: in a rapid communication published in Eurosurveillance, ECDC and co-authors from Public Health England and The National AIDS Trust summarise the progress towards HIV elimination in 52 countries in Europe and Central Asia. The main issues: diagnosing those who are unaware of their HIV infection and treating them.